Overview
- Mass vaccination began in Botucatu, Maranguape and Nova Lima using Butantan-DV, with 204,100 doses allocated, including 80,000 for Botucatu.
- The Health Ministry is targeting 40% to 50% coverage in the 15–59 age group to assess protection and potential reduction in community transmission.
- About 1.1 million primary care professionals are slated to be immunized starting February 9, contingent on an additional 1.1 million doses due by January 31.
- To expand supply, Butantan signed a technology-transfer partnership with WuXi Vaccines, with officials projecting 25–30 million doses available this year.
- Clinical studies of Butantan-DV reported approximately 74% efficacy against overall dengue, over 91% against severe disease and 100% protection from hospitalization, while QDenga remains available to ages 10–14 with 9 million doses purchased for 2026 and 9 million for 2027.